2017
DOI: 10.1136/annrheumdis-2017-212268
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: ObjectivesTo compare the effects of rituximab versus placebo on salivary gland ultrasound (SGUS) in primary Sjögren’s syndrome (PSS) in a multicentre, multiobserver phase III trial substudy.MethodsSubjects consenting to SGUS were randomised to rituximab or placebo given at weeks 0, 2, 24 and 26, and scanned at baseline and weeks 16 and 48. Sonographers completed a 0–11 total ultrasound score (TUS) comprising domains of echogenicity, homogeneity, glandular definition, glands involved and hypoechoic foci size. B… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
55
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 83 publications
(61 citation statements)
references
References 24 publications
5
55
0
1
Order By: Relevance
“…Two randomized controlled trials also used SGUS for monitoring of the therapeutic response of rituximab in patients with pSS. Similar to our study, both trials also defined improvement in echostructure as a ≥1-point decrease in the score after 24 and 48 weeks of treatment [9,10]. However, one-point changes in SGUS scores could be marginal and insufficient to provide clinical significance.…”
Section: Discussionsupporting
confidence: 76%
See 1 more Smart Citation
“…Two randomized controlled trials also used SGUS for monitoring of the therapeutic response of rituximab in patients with pSS. Similar to our study, both trials also defined improvement in echostructure as a ≥1-point decrease in the score after 24 and 48 weeks of treatment [9,10]. However, one-point changes in SGUS scores could be marginal and insufficient to provide clinical significance.…”
Section: Discussionsupporting
confidence: 76%
“…Recently, two trials have used SGUS to monitor the therapeutic response to rituximab. These two trials demonstrated the improvement of SGUS scores after treatment with rituximab, suggesting SGUS as an imaging biomarker for pSS [9,10]. Despite this promise, evidence on the natural history of SGUS findings in patients with pSS is scarce.…”
Section: Introductionmentioning
confidence: 99%
“…Finally, the TRial of Anti‐B‐Cell Therapy In patients with primary SS (TRACTISS) study was reported in two publications (Bowman et al., ; Fisher et al., ). Bowman et al.…”
Section: Resultsmentioning
confidence: 99%
“…Fisher et al. () evaluated salivary gland ultrasounds at baseline and at least once after that. They scored improvement as Total Ultrasound Score (TUS), a combined measure of echogenicity, consistency, definition, glands involved, and size of hypoechoic foci.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation